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Abstract
Background: Severe injury induces an acute coagulopathy associated with increased mortality. This study
compared the Thrombelastography (TEG) and biomarker profiles upon admission in trauma patients.
Methods: Prospective observational study of 80 trauma patients admitted to a Level I Trauma Centre. Data on
demography, biochemistry including standard coagulation tests, hematology, transfusions, Injury Severity Score (ISS)
and TEG were recorded. Retrospective analysis of thawed plasma/serum for biomarkers reflecting tissue injury
(histone-complexed DNA fragments), sympathoadrenal activation (adrenaline, noradrenaline), coagulation
activation/inhibition and fibrinolysis (sCD40L, protein C, activated Protein C, tissue-type plasminogen activator,
plasminogen activator inhibitor-1, D-dimer, prothrombinfragment 1+2, plasmin/a2-antiplasmin complex, thrombin/
antithrombin complex, tissue factor pathway inhibitor, antithrombin, von willebrand factor, factor XIII). Comparison
of patients stratified according to ISS/TEG maximum clot strength. Linear regression analysis of variables associated
with clot strength.
Results: Trauma patients had normal (86%), hypercoagulable (11%) or hypocoagulable (1%) TEG clot strength; one
had primary hyperfibrinolysis. Hypercoagulable patients had higher age, fibrinogen and platelet count (all p < 0.05),
none had increased activated partial thromboplastin time (APTT) or international normalized ratio (INR) and none
required massive transfusion (> 10 red blood cells the initial 24 h). Patients with normal or hypercoagulable TEG
clot strength had comparable biomarker profiles, but the few patients with hypocoagulable TEG clot strength and/
or hyperfibrinolysis had very different biomarker profiles.
Increasing ISS was associated with higher levels of catecholamines, histone-complexed DNA fragments, sCD40L,
activated protein C and D-dimer and reduced levels of non-activated protein C, antithrombin, fibrinogen and factor
XIII (all p < 0.05). Fibrinogen and platelet count were associated independently with clot strength in patients with
ISS ≤ 26 whereas only fibrinogen was associated independently with clot strength in patients with ISS > 26. In
patients with ISS > 26, adrenaline and sCD40L were independently negatively associated with clot strength.
Conclusions: Trauma patients displayed different coagulopathies by TEG and variables independently associated
with clot strength changed with ISS. In the highest ISS group, adrenaline and sCD40L were independently
negatively associated with clot strength indicating that these may contribute to acute coagulopathy.
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Many severely injured patients develop an acute coagulo-
pathy of trauma (ACT) already at the scene of the acci-
dent [1,2] and 25-35% are coagulopathic upon admission,
a condition associated with a four-fold increase in mor-
tality [3]. Previous studies have defined ACT as increases
in plasma based coagulation tests (activated partial
thromboplastin time (APTT), partial thrombin time
(PTT), prothrombin time (PT), international normalized
ratio (INR)) [4] but there is emerging evidence that the
viscoelastic whole blood tests, Thrombelastography
(TEG) and Rotation Thromboelastometry (ROTEM), can
detect and discriminate between different types of trau-
m a t i cc o a g u l o p a t h y[ 5 ]s i n c et h i se n t i t ya p p e a r st o
change from normal to hypercoagulability, hypocoagul-
ability and finally hyperfibrinolysis with increasing injury
severity [1,6-11]. Immediate identification of the specific
type of traumatic coagulopathy by TEG/ROTEM is of
critical importance in order to goal-direct transfusion
therapy and e.g. administer plasma, platelets, fibrinogen
and/or antifibrinolytics to patients with evident hypocoa-
gulability and/or hyperfibrinolysis [12,13]. We have used
TEG to monitor hemostasis and guide transfusion ther-
apy in massively bleeding patients since 2004 and this
has significantly improved survival in these patients [14].
To our knowledge, no studies have directly compared
outcomes in ratio-driven vs. TEG guided resuscitated
bleeding trauma patients, and in addition to our previous
finding of improved survival in bleeding patients resusci-
tated goal-directed according to TEG [14] we recently
reported, in a meta-analysis of 16 studies of massively
bleeding trauma patients, that the highest ratio of FFP
and/or PLT to RBC was associated with a significantly
reduced mortality (OR 0.49 (95% CI 0.43-0.57), p <
0.0001) as compared to the lowest ratio [15]. TEG/
ROTEM were recently recommended internationally as
gold standard point-of-care tests in bleeding trauma
patients [16,17].
Though the exact pathophysiologic mechanism(s) of the
ACT are unclear, retrospective analyses of circulating bio-
markers have pointed to downstream effects of tissue
injury, sympathoadrenal activation and hypovolemic/
hemorrhagic shock as drivers [3,4,18] of an enhanced early
protein C (PC) activation, hyperfibrinolysis [3,4,18] and
endothelial damage [19], which may all contribute to the
coagulopathy. Despite the recognized differences in pre-
senting TEG/ROTEM profile in trauma patients [5], no
studies have so far reported on circulating biomarker
levels of tissue injury, sympathoadrenal activation and coa-
gulopathy in trauma patients with different TEG profiles.
The primary aim of this study was to investigate bio-
markers of sympathoadrenal activation, tissue injury,
coagulation activation/inhibition and fibrinolysis in
trauma patients stratified according to injury severity
and TEG profile upon admission. A secondary aim was
to identify biomarkers independently associated with
TEG maximum clot strength as this parameter is
the parameter most strongly associated with bleeding,
transfusion requirements and outcome in massively
bleeding patients [5]. We hypothesized that progressive
coagulopathy by TEG (from normal to hypercoagulabil-
ity, hypocoagulability and hyperfibrinolysis) would be
accompanied by evidence of increased sympathoadrenal




Prospective observational cohort study of trauma patients
admitted directly to a Level I Trauma Centre (TC) at a ter-
tiary hospital (Rigshospitalet, Copenhagen, Denmark, cov-
ering 2.5 million inhabitants) between March 2010 and
November 2010. The study is part of an ongoing larger
multicentre study [21], Activation of Coagulation and
Inflammation after Trauma 3 (ACIT3), approved by the
Regional Ethics Committee (H-4-2009-139), the Danish
Data Protection Agency and conducted in accordance
with the 2nd Declaration of Helsinki. Written informed
consent was obtained from the patients or next of kin.
Here we report on preliminary findings related to a cohort
of 80 patients recruited to the ACIT3 study.
Patient selection
ACIT3 study inclusions: Adult trauma patients (≥ 18
years) who met criteria for full trauma team activation
and had an arterial cannula inserted. The latter was cho-
sen since only patients with expected severe injuries have
an arterial cannula placed immediately upon TC admis-
sion. Exclusion criteria, according to the multicentre study
protocol [21], were arrival in the TC > 2 hours after injury;
> 2,000 ml of intravenous fluids administered before hos-
pital arrival; transfer from another hospital or burns > 5%
total body surface area. Patients were retrospectively
excluded if they were taking anticoagulant/antiplatelet
medications (except aspirin); had moderate or severe liver
disease or had known bleeding diathesis.
T h e8 0i n c l u d e dp a t i e n t sw e r es e l e c t e df r o mt h ef i r s t1 0 0
patients recruited to the ACIT3 study with complete data.
We intended to include 80 patients because we measured
an extensive number of biomarkers by ELISA, with each
ELISA kit providing analysis of 80 samples. We aimed at
including the most severely injured and/or coagulopathic
patients and selected the 80 patients according to: Out-
come (mortality or ICU admission post trauma; yes), trans-
fusion of RBC within 6 hours (yes), RTS (< 5.00, we had
not access to ISS before later in the study period) or coagu-
lopathy (APTT ≥ 35 sec, INR ≥ 1.2, Ly30 > 1%/Cl30 < 95%;
yes). This yielded 70 severely injured/coagulopathic
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Page 2 of 10patients, and additionally 10 patients (age 48 years (IQR
43-52), 60% males) were selected blinded from the remain-
ing 30 patients to match their age and gender (see Table 1
for details on demography, injury severity etc.). The 20
patients not included in this study, had, compared to the
included patients, comparable age and gender (41 years
(IQR 33-53), 40% males) and APTT (26 (IQR 23-27), NS)
but had, as expected, lower ISS (4 (IQR 2-10), p < 0.001),
mortality (0%, p = 0.037) and INR (1.1 (IQR 1.0-1.1), p =
0.007). Two of the 20 patients not included had a hyper-
coagulable TEG (MA > 69, 10%).
Data on demography, clinical and biochemical para-
meters, investigations, management and 30-day mortality
were recorded and ISS scores were obtained from the
Trauma Audit & Research Network (TARN) database.
No patients received Tranexamic acid or catecholamines
(Adrenaline or Noradrenaline) for hemodynamic stabiliza-
tion prior to blood sampling.
Blood sampling
Blood was sampled immediately upon arrival for standard
arterial blood gas (ABG, Radiometer ABL 725/735, Copen-
hagen, Denmark), routine biochemistry and research ana-
lyses (citrate, heparin, EDTA plasma, serum). Routine
biochemistry samples were analyzed in a DS/EN ISO
15189 standardized laboratory by a Sysmex XE-2100
(hemoblobin, platelets, leukocytes) and ACL TOP (APTT,
INR, AT, fibrinogen). Samples for functional hemostatic
assays were kept at room temperature (RT) until analyzed
precisely 1 h after sampling. Plasma samples were ice-
cooled immediately whereas serum samples were kept at
RT for 1 h before centrifugation (one (serum) or two
(plasma) times 1800 g at 5°C for 10 min) and storage at
-80°C.
Enzyme linked immunosorbent assay (ELISA)
measurements
Soluble biomarkers of tissue injury, sympathoadrenal acti-
vation, coagulation activation/inhibition and fibrinolysis
were measured in uniplicate by commercially available
immunoassays according to the manufactures recommen-
dations. In each patient, a total of 15 biomarkers were
measured corresponding to a total of 15*80 = 1,280 mea-
surements, with only 3 missing measurements. The bio-
markers were analyzed in EDTA or citrate plasma as
follows: EDTA plasma: adrenaline and noradrenaline (2-
CAT ELISA, Labor Diagnostica Nord GmbH & Co. KG,
Nordhorn, Germany; lower limit of detection (LLD) 11
pg/ml (adrenaline, normal reference < 100 pg/ml) and 44
pg/ml (noradrenaline, normal reference < 600 pg/ml),
respectively. Histone-complexed DNA fragments (hcDNA,
Cell Death Detection ELISA
PLUS, Roche, Hvidovre, Den-
mark; LLD not stated, relative quantification); D-dimer
(ADI; LLD 2-4 ng/ml) and sCD40L (R&D Systems Europe;
LLD 4.2 pg/ml). Citrate plasma: protein C (PC, Helena
Laboratories, Beaumont, TX, US; LLD 5% of reference
plasma); activated protein C (APC, USCNLIFE; LLD 4.2
pg/ml); tissue-type plasminogen activator (tPA, ADI,
detects sc-tPA, tc-tPA and tPA/PAI-1 complexes; LLD 1
ng/ml); plasminogen activator inhibitor-1 (PAI-1, Assay-
pro; LLD 0.2 ng/ml); prothrombinfragment 1 and 2
(PF1.2, USCNLIFE; LLD 0.043 nmol/l); plasmin/a2-anti-
plasmin complex (PAP, ADI; LLD not stated); thrombin/
antithrombin complex (TAT, USCNLIFE; LLD 0.215 ng/
ml); tissue factor pathway inhibitor (TFPI, ADI, detects
intact TFPI, truncated TFPI, TF/FVIIa/TFPI complexes;
LLD 0.18 ng/ml); von Willebrand Factor antigen (vWF,
Helena Laboratories, LLD 5% of reference plasma); factor
XIII (FXIII, Assaypro; LLD 50 pg/ml).
Thrombelastography (TEG)
Whole blood clot formation was assessed in 3.2% citrated
whole blood using a TEG
® 5000 Hemostasis Analyzer
System (Haemonetics Corp., MA, US), according to the
manufacturers recommendations. All analyses were con-
ducted within 2 hours from blood sampling at 37°C. The
variables recorded were [normal range reported by Hae-
monetics Corp.]: reaction time (R [3-8 min], rate of initial
fibrin formation), angle (a [55-78 degrees], clot growth
kinetics, reflecting the thrombin burst), maximum ampli-
tude (MA, clot strength [51-69 mm], reflecting maximum
clot strength) and lysis after 30 min (Ly30 [0-8%], pro-
portional reduction in the amplitude after MA, reflecting
fibrinolysis) [5]. Patients were stratified according to
TEG MA into the following groups: Normocoagulable
(MA from 51-69 mm, n = 69), hypercoagulable (MA > 69
mm, n = 9), hypocoagulable (MA < 51, n = 1) and hypo-
coagulable hyperfibrinolysis (MA < 51 and Ly30 > 8%,
n = 1). The day-to-day CV% of TEG MA is < 7% in our
laboratory [22].
Statistics
Statistical analysis was performed using SAS 9.1 (SAS
Institute Inc., Cary, NC, US). Data from patients strati-
fied according to ISS group (ISS > 26, ISS 15-26, ISS <
1 5 )o rm a x i m u mc l o ts t r e n g t h( T E GM A ,n o r m a lv s .
hypercoagulable) were compared by Kruskal-Wallis and
Bonferroni adjusted Wilcoxon Rank Sum post hoc tests,
Wilcoxon Rank Sum tests and Chi-square/Fischer exact
tests, as appropriate. The contribution of platelets, fibri-
nogen, FXIII and biomarkers to the variation in maxi-
mum clot strength was investigated separately in each
ISS group by univariate and multivariate linear regres-
sion analysis. Data are presented as medians with inter
quartile ranges (IQR). P-values < 0.05 were considered
significant.
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Page 3 of 10Table 1 Demography, injury severity, transfusion requirements, mortality, biochemistry and hemostasis,
thrombelastography and biomarkers of coagulopathy in 80 trauma patients stratified according to injury severity score (ISS)
ISS > 26 ISS 15-26 ISS < 15 p-value
Demography, injury severity, transfusion and mortality
N2 3 2 6 3 0
Age yrs 45 (25-71) 57 (43-65) 42 (28-49) 0.034
c
Gender m% (n) 74% (17) 62% (16) 67% (20) NS
Blunt trauma % (n) 96% (22) 96% (25) 83% (25) 0.142
ISS score 34 (29-36) 22 (17-25) 9 (5-10) NA
sTBI % (n) 17% (4) 46% (12) 29% (6) 0.091
GCS (PH) score 7 (3-13) 11 (6-15) 15 (12-15) 0.002
a
Crystalloids (PH) ml 900 (250-1250) 275 (0-500) 250 (25-750) 0.013
a, b
RBC 0-24 h units 2 (0-12) 1 (0-3) 0 (0-1) 0.007
a
FFP 0-24 h units 2 (0-9) 0 (0-1) 0 (0-0) 0.003
a
PLT 0-24 h units 0 (0-4) 0 (0-0) 0 (0-0) 0.006
a
MT (> 10 RBC in 24 h) % (n) 35% (8) 4% (1) 3% (1) 0.001
a, b
Mortality % (n) 39% (9) 15% (4) 3% (1) 0.003
a
Shock, sympathoadrenal activation, cell damage, biochemistry and hemostasis
SBP (PH) mmHg 150 (108-156) 136 (125-152) 130 (123-143) NS
pH 7.31 (7.25-7.33) 7.40 (7.307.40) 7.37 (7.33-7.41) 0.001
a, b
Lactate mmol/l 1.7 (1.2-2.2) 2.5 (1.3-3.1) 1.5 (0.9-2.1) 0.049
c
SBE mmol/l -3.6 (-5.7- -1.9) -2.7 (-4.6- -0.5) -1.0 (-1.8-0.7) 0.005
a
Adrenaline pg/ml 1,062 (328-1,549) 292 (126-1,077) 247 (86-354) 0.002
a
Noradrenaline pg/ml 1,235 (434-1,511) 652 (210-1,288) 332 (217-1,036) 0.040
a
hcDNA % 16.9 (5.6-27.0) 5.6 (2.4-10.3) 0.4 (0.0-9.3) <0.001
a
Hemoglobin mmol/l 8.0 (6.3-9.2) 8.6 (7.2-9.1) 8.4 (7.7-8.9) NS
Platelet count 10
9/l 217 (165-252) 193 (173-260) 211 (191-240) NS
Fibrinogen g/l 2.0 (1.4-2.2) 2.4 (2.1-2.9) 2.6 (2.3-2.9) 0.002
a, b
FXIII microg/ml 25 (20-30) 30 (22-40) 32 (28-41) 0.001
a
vWF % 190 (110-218) 200 (132-223) 204 (146-230) NS
APTT > 35 sec % 22% (5) 4% (1) 0% 0.009
a
INR > 1.2 % 43% (10) 0% 0% <0.001
a, b
Thrombelastography
R min 5.1 (4.8-5.9) 5.9 (5.1-6.7) 6.0 (5.3-6.4) 0.046
Angle degrees 65 (62-68) 67 (62-7) 66 (62-70) NS
MA mm 63 (58-67) 64 (62-68) 63 (61-67) NS
Ly30 % 0.2 (0.0-0.7) 0.0 (0.0-0.2) 0.3 (0.0-1.0) 0.040
Platelet activation and thrombin generation
sCD40L pg/ml 394 (281-551) 327 (251-406) 250 (195-305) 0.006
a
PF1.2 nmol/l 4.1 (1.1-13.0) 15.1 (4.1-45.3) 4.2 (1.6-9.5) 0.026
b, c
TAT ng/ml 36 (32-41) 39 (33-44) 35 (29-40) 0.181
Natural anticoagulation
AT 10
3 U/l 0.89 (0.69-0.96) 0.9 (0.8-1.00) 0.98 (0.90-1.07) 0.002
a
PC % 92 (75-116) 107 (96-123) 117 (100-129) 0.031
a
APC ng/ml 10.4 (9.4-12.1) 10.5 (8.7-13.5) 8.0 (6.8-10.5) 0.005
a, c
TFPI ng/ml 64 (48-86) 67 (52-80) 54 (41-74) NS
Fibrinolysis
D-dimer ng/ml 173 (172-176) 170 (144-175) 128 (36-148) <0.001
a, c
tPA ng/ml 7.3 (5.5-15.4) 7.8 (4.7-13.7) 5.2 (2.0-9.9) 0.063
PAI-1 ng/ml 24 (11-37) 31 (14-68) 20 (13-27) 0.145
PAP ng/ml 316 (22-599) 475 (83-1152) 225 (54-393) 0.159
Data are presented as medians (IQR) or n (%), with p-values shown for variables with p < 0.200, and in bold for p < 0.050. ISS groups were compared by Kruskal-
Wallis and Bonferroni adjusted Wilcoxon Rank Sum post hoc tests, Wilcoxon Rank Sum tests and Chi-square/Fischer exact tests, as appropriate.
aISS gr. 0 (ISS < 15) vs. 2 (ISS > 26) Bonferroni adjusted p < 0.05;
bISS gr. 1 (ISS 15-26) vs. 2 (ISS > 26) Bonferroni adjusted p < 0.05;
cISS gr. 0 (ISS < 15) vs. 1 (ISS
15-26) Bonferroni adjusted p < 0.05.
ISS, injury severity score; sTBI, severe Traumatic Brain Injury, Abbreviated Injury Score head > 3; PH, pre-hospital at the site of injury; GCS, Glascow Coma Score
scale; RBC, red blood cells; FFP, fresh frozen plasma; PLT, platelet concentrates; MT, > 10 RBC the initial 24 hours; SBP, systolic blood pressure; APTT, activated
partial thromboplastin time; INR, international normalized ratio. Biomarker abbreviations, see Materials and Methods section, ELISA.
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Study patients
The 80 patients presented with ISS in the entire range (ISS
> 26 n = 23, 15-26 n = 26 and < 15 n = 30), with demogra-
phy, injuries, transfusion requirements, mortality, bio-
chemistry, thrombelastography and biomarkers as
depicted in Table 1. Most patients (96%) were referred by
mobile emergency care units (MECU) staffed with
anesthetists (26% by helicopter) and blood samples were
drawn a median of 68 min (IQR 48-88) after the injury.
Increasing ISS was associated with higher mortality (18%
overall mortality), lower Glascow Coma Score scale,
increased volume of prehospital crystalloids and higher
blood transfusion requirements, catecholamines, biomar-
kers of tissue injury and shock (pH, lactate, SBE) (Table 1).
Mortality causes were in brief: Of the 11 patients whom
expired in the group with normal TEG, eight died within
24 h (50% from severe (s) TBI) and three died on days 7, 7
and 24 post-injury, two from sTBI sequels. The two
patients who expired in the group with hypercoagulable
TEG died days 7 and 8 post-injury, one from sTBI sequels.
The patients with hyperfibrinolysis died within 24 h from
severe non-TBI injuries.
Injury severity and coagulopathy
ACT defined by APTT or INR above normal, were present
in 15% of all patients (8% and 13% had increased APTT
and INR, respectively) with increasing prevalence in the
highest ISS group (Table 1). Furthermore, increasing ISS
was associated with reduced fibrinogen and FXIII levels
and also with reduced TEG R time and increased Ly30.
With regards to biomarkers of coagulation activation,
increasing ISS was associated with increased sCD40L, a
biomarker of platelet activation, and with significantly
increased PF1.2 in moderately injured patients (ISS 15-
26) as compared to both more severely and less injured
patients. A similar tendency was observed for TAT
(Table 1). Considering biomarkers of natural anticoagula-
tion and fibrinolysis, AT and non-activated PC declined
with increasing ISS whereas APC and D-dimer increased
(Table 1).
Maximum clot strength and biomarkers of coagulopathy
When stratifying patients according to normal (n = 69)
vs. hypercoagulable (n = 9, 11%) clot strength (TEG MA),
patients with hypercoagulable clot strength were older,
had a higher platelet count and fibrinogen level and also
tended to have a higher FXIII level (Table 2). No patients
in the hypercoagulable group had increased APTT or
INR or required massive transfusion, and pre-hospital
administration of fluids was comparable in the patients
with normal or hypercoagulable clot strength (Table 2).
Furthermore, hypercoagulable patients had faster clot
growth kinetics (TEG angle, reflecting the thrombin
burst) and a tendency towards reduced fibrinolysis (TEG
Ly30) (Table 2).
Two patients presented with hypocoagulability and pri-
mary hyperfibrinolysis, respectively, and these are dis-
played separately in Table 2 for comparison, though no
attempt was done to statistically compare these patients
with the normal or hypercoagulable groups. It is notable
that fibrinogen, FXIII and thrombin generation (PF1.2)
was profoundly reduced in these two patients and that
adrenaline, hcDNA, sCD40L and tPA was markedly
increased in the patient with primary hyperfibrinolysis
(Table 2).
Injury severity and predictors of maximum clot strength
Given that platelets, fibrinogen and FXIII contribute sig-
nificantly to TEG clot strength [23-25], we investigated
the association between these variables and maximum
clot strength in patients stratified according to ISS and
also investigated the influence of the measured biomar-
kers on the independent association between fibrinogen,
platelet count, FXIII and clot strength (Table 3).
By univariate linear regression analysis, fibrinogen was
associated with clot strength in all ISS groups whereas
FXIII was only associated with clot strength in the highest
ISS group and platelets were only associated with clot
strength in the lower ISS groups. When including fibrino-
gen, platelets and FXIII in a multivariate model (Model 1),
fibrinogen was the only variable independently associated
with clot strength in the highest ISS groups whereas both
fibrinogen and platelets were independently associated
with clot strength in the two lower ISS groups (Table 3).
When confronting the multivariate model (fibrinogen,
platelets, FXIII) with the measured biomarkers, sCD40L
was independently negatively associated with clot
strength only in the highest ISS group and importantly,
inclusion of sCD40L made platelets independently posi-
tively associated with clot strength also in these patients
(Model 2, Table 3). Adrenaline was also independently
negatively associated with clot strength only in the high-
est ISS group (b -2.20 (SE 0.81), p = 0.014; change in mm
MA per 1 ng/ml increase in adrenaline) whereas APC
was independently negatively associated with clot
strength only in the lowest ISS group (b -0.53 SE), p =
0.009; change in mm MA per 1 ng/ml higher APC).
None of the other measured biomarkers were indepen-
dently associated with clot strength in any ISS groups.
Discussion
The present study confirms that trauma patients present a
spectrum of different coagulopathies that can be identified
by TEG and demonstrates that hypercoagulable trauma
patients are older and have higher fibrinogen level and
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thrombelastography and biomarkers of coagulopathy in 80 trauma patients stratified according to TEG profile









(51-69 mm) (> 69 mm) (< 51 mm) (< 51 mm/> 8%)
Demography, injury severity, transfusion and mortality
N6 9 9 1 1
Age yrs 44 (32-58) 72 (59-80) 63 80 0.006
Gender m% (n) 68% (47) 56% (5) 100% 100% NS
Blunt trauma % (n) 90% (62) 100% 100% 100% NS
ISS score 18 (10-29) 17 (16-20) 25 50 NS
sTBI % (n) 30% (18) 33% (3) 100% 0% NS
GCS (PH) score 13 (6-15) 12 (9-14) 7 6 NS
Crystalloids (PH) ml 300 (0-1000) 500 (200-500) 0 500 NS
RBC 0-24 h units 0 (0-4) 0 (0-1) 0 45 NS
FFP 0-24 h units 0 (0-3) 0 (0-0) 0 36 NS
PLT 0-24 h units 0 (0-1) 0 (0-0) 0 15 NS
MT (> 10 RBC in 24 h) % (n) 14% (10) 0% 0% 100% 0.159
Mortality % (n) 16% (11) 22% (2) 0% 100% NS
Shock, sympathoadrenal activation, cell damage, biochemistry and hemostasis
SBP (PH) mmHg 135 (122-149) 129 (100-153) 170 95 NS
pH 7.34 (7.29-7.38) 7.37 (7.31-7.41) 7.38 7.06 NS
Lactate mmol/l 1.9 (1.4-2.9) 2.3 (1.4-2.8) 1.3 8.4 NS
SBE mmol/l -2.1 (-4.1–0.2) 0.3 (-2.0-0.7) -1.9 -10.7 0.127
Adrenaline pg/ml 295 (112-976) 1,163 (191-1,471) 298 5,427 0.169
Noradrenaline pg/ml 638 (276-1,307) 1,146 (120-2,540) 731 549 NS
HcDNA % 4.7 (0.1-13.5) 10.0 (7.2-16.4) 9.8 17.1 0.126
Hemoblobin mmol/l 8.4 (7.6-9.1) 7.5 (6.5-8.8) 8.8 6.4 NS
Platelet count 10
9/l 206 (173-251) 275 (185-306) 117 172 0.045
Fibrinogen g/l 2.3 (2.0-2.7) 3.1 (3.0-3.4) 1.1 1.1 < 0.001
FXIII microg/ml 29 (24-36) 37 (29-43) 21 18 0.096
vWF % 200 (127-225) 190 (151-222) 124 203 NS
APTT > 35 sec % (n) 7% (5) 0% 0% 100% NS
INR > 1.2 % (n) 13% (9) 0% 0% 100% 0.134
Thrombelastography
R min 5.6 (4.9-6.4) 5.4 (5.1-5.7) 6.7 6.1 NS
Angle degrees 65 (62-69) 70 (67-73) 41 54 0.027
MA mm 63 (61-66) 71 (69-73) 49 33 NA
Ly30 % 0.2 (0.0-0.6) 0.0 (0.0-0.0) 0 78 0.076
Platelet activation and thrombin generation
sCD40L pg/ml 292 (223-417) 332 (263-406) 399 1,431 NS
PF1.2 nmol/l 6.6 (2.7-18.0) 4.5 (1.0-22.4) 1.0 0.4 NS
TAT ng/ml 37 (31-43) 36 (31-44) 29 38 NS
Natural anticoagulation
AT 10
3 U/l 0.92 (0.82-1.02) 0.95 (0.88-0.98) 0.98 0.61 NS
PC % 108 (91-124) 108 (100-135) 138 71 NS
APC ng/ml 9.8 (7.6-12.1) 9.3 (9.1-11.1) 13.7 10.3 NS
TFPI ng/ml 58 (44-78) 78 (57-84) 126 68 0.075
Fibrinolysis
D-dimer ng/ml 166 (122-173) 170 (141-174) 179 173 NS
tPA ng/ml 6.9 (3.6-12.0) 12.1 (5.8-14.8) 2.6 25.4 0.123
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Page 6 of 10platelet count. Furthermore, increasing injury severity was
associated with increased shock, sympathoadrenal activa-
tion, tissue injury, platelet activation, protein C activation
(higher activated PC, lower non-activated PC), hyperfibri-
nolysis and reduced fibrinogen and FXIII levels. Finally, in
the most severely injured patients (highest ISS group),
adrenaline and sCD40L were independently negatively
associated with maximum clot strength and platelet count
alone was only associated with clot strength after adjusting
for platelet activation level (sCD40L).
Trauma is a leading cause of death and disability world-
wide and hemorrhage is responsible for the majority of
potentially preventable deaths. Death due to exsanguina-
tion occurs early (50% within 2 hours) after the injury [26]
emphasizing that immediate diagnosis of existing coagulo-
pathies by TEG/ROTEM is of critical importance to
enable goal-directed therapy early in the resuscitation
phase [12,14].
In accordance with previous studies [1,6-11] TEG identi-
fied a spectrum of different coagulopathies in trauma
patients, with hypercoagulability being the most frequent
[6] and in this study associated with high age and high
fibrinogen level and platelet count. In contrast to some
previous studies [6,11], but consistent with others [10], no
difference in injury severity between patients with normal
and hypercoagulable TEG was found. Though not statisti-
cally significant, it is notable that no hypercoagulable
patients were massively transfused or had ACT according
to APTT/INR, a finding in accordance with previous stu-
dies [6]. Furthermore, it is notable that the hypercoagul-
able and normal patients had comparable mortality
despite a considerably higher age in the hypercoagulable
group. It is tempting to speculate that a hypercoagulable
response to moderate (survivable) trauma may be optimal
from an evolutionary perspective by promoting hemosta-
sis. Given this, the hypocoagulability and/or hyperfibrino-
lysis that may accompany severe (unsurvivable) injury may
reflect a less well adapted exaggerated response to exces-
sive systemic endothelial activation and damage along
with extremely low flow and hypoperfusion [20].
Table 2 Demography, injury severity, transfusion requirements, mortality, biochemistry and hemostasis, thrombelasto-
graphy and biomarkers of coagulopathy in 80 trauma patients stratified according to TEG profile (normal, hypercoa-
gulability, hypocoagulability, hyperfibrinolysis) (Continued)
PAI-1 ng/ml 22 (12-38) 33 (24-68) 8 24 NS
PAP ng/ml 283 (45-619) 510 (331-1154) 0 316 0.126
Data are presented as medians (IQR) or n (%), with p-values shown for variables with p < 0.200, and in bold for p < 0.050.
aOnly patients with normal or hypercoagulable TEG MA were compared (Wilcoxon Rank Sum tests or Chi-square/Fischer exact tests, as appropriate) but data are
presented on the two patients that displayed hypocoagulability (MA < 51 mm) and hypocoagulable hyperfibrinolysis (MA < 51 mm and Ly30 > 8%).
ISS, injury severity score; sTBI, severe Traumatic Brain Injury, Abbreviated Injury Score head > 3; PH, pre-hospital at the site of injury; GCS, Glascow Coma Score
scale; RBC, red blood cells; FFP, fresh frozen plasma; PLT, platelet concentrates; MT, > 10 RBC the initial 24 hours; SBP, systolic blood pressure; APTT, activated
partial thromboplastin time; INR, international normalized ratio. Biomarker abbreviations, see Materials and Methods section, ELISA.
Table 3 Univariate and multivariate contribution of fibrinogen, platelets, FXIII and sCD40L to the variation in TEG
maximum amplitude (MA) in trauma patients stratified according to ISS (gr. 2 ISS > 26, gr. 1 ISS 15-26, gr. 0 ISS < 15)
Univariate Multivariate (model 1) Multivariate (model 2)
Unit b (SE) p b (SE) p b (SE) p
ISS > 26 (n = 23) R
2 = 0.47 R
2 = 0.76
Fibrinogen 1 g/l 6.59 (1.85) 0.002 5.61 (1.86) 0.007 4.65 (1.31) 0.002
Platelets 10 *10
9/l 0.48 (0.28) 0.094 0.29 (0.25) 0.438 0.42 (0.18) 0.032
FXIII 1% 0.43 (0.20) 0.043 0.24 (0.19) 0.212 0.17 (0.13) 0.210
sCD40L 100 pg/ml -1.62 (0.53) 0.006 - - -1.62 (0.35) < 0.001
ISS 15-26 (n = 26) R
2 = 0.75 R
2 = 0.76
Fibrinogen 1 g/l 6.84 (1.08) < 0.001 6.33 (0.96) < 0.001 5.84 (1.04) < 0.001
Platelets 10 *10
9/l 0.41 (0.20) 0.047 0.37 (0.13) 0.011 0.44 (0.14) 0.006
FXIII 1% 0.13 (0.11) 0.245 0.01 (0.07) 0.847 0.03 (0.07) 0.712
sCD40L 100 pg/ml -0.95 (0.89) 0.300 - - -0.73 (0.61) 0.250
ISS < 15 (n = 30) R
2 = 0.41 R
2 = 0.41
Fibrinogen 1 g/l 3.55 (1.12) 0.004 3.26 (1.05) 0.005 3.29 (1.07) 0.005
Platelets 10 *10
9/l 0.34 (0.13) 0.017 0.30 (1.05) 0.019 0.28 (0.13) 0.038
FXIII 1% 0.00 (0.04) 0.986 0.00 (0.03) 0.995 -0.00 (0.03) 0.984
sCD40L 100 pg/ml 0.38 (0.44) 0.403 - - 0.15 (0.38) 0.691
Univariate and multivariate regression analysis showing regression coefficients (b) with standard errors (SE) and p-values, with p-values in bold for variables with
p < 0.05. The b corresponds to the predicted change in TEG MA (mm) associated with one unit increase in fibrinogen, platelet count, FXIII and/or sCD40L.
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with previous findings in trauma patients [1,7-9], but we
found a lower than expected prevalence of hypocoagulabil-
ity [1,6]. The latter may be due to the relatively low num-
ber of severely injured and/or shocked patients in the
present study, which may also explain the low prevalence
of patients with ACT according to APTT and INR.
Though the 15% prevalence of ACT in the present study
is within the range previously reported in other trauma
studies (from 10-34%) [27], this relatively low proportion
of patients with ACT should be taken into account when
interpreting the results from the present study.
Though we lacked statistical power to compare patients
with hypocoagulability or hyperfibrinolysis to patients with
a normal TEG, the high level of sympathoadrenal activa-
tion, tissue injury, platelet activation, PC activation and
tPA release in the patient with primary hyperfibrinolysis
concurs with the biomarker profile expected to yield
hyperfibrinolysis [3,4,20]. However, this finding reported
here needs to be confirmed in a larger study powered to
investigate biomarkers in patients with hypocoagulable or
hyperfibrinolytic TEG profiles.
Increasing injury severity was associated with lower
fibrinogen levels and importantly also with lower FXIII
levels and higher prevalence of patients with ACT accord-
ing to APTT or INR. The association between injury
severity and fibrinogen, APTT and INR is well established
[3,4] whereas the negative association between ISS and
FXIII has not been described previously, despite an estab-
lished association between low FXIII levels and increased
bleeding following e.g., cardiac surgery and neurosurgery
[28]. In accordance with previous studies, higher ISS was
also associated with evidence of increased sympathoadre-
nal activation, tissue injury [18,19], PC activation and
hyperfibrinolysis [3,4,18,19]. In contrast to previous studies
of ACT reporting solely on decreases in non-activated PC
as indirect evidence of PC activation [3,4], the present
study is to our knowledge the first to directly demonstrate
enhanced PC activation with increasing injury severity,
evidenced by increased activated PC in the highest ISS
groups, occurring along with a previously described
decline in non-activated PC in these patients.
Though not statistically significant, the TEG profile
changed towards reduced R time and increased fibrinolysis
with increasing injury severity, a finding also in accordance
with previous findings [6-8].
Maximum clot strength is a strong predictor of bleeding
and transfusion requirements in trauma patients
[6,10,11,29], explaining why we investigated variables inde-
pendently associated with this. In the two lower ISS
groups, the fibrinogen level and platelet count were both
independently associated with clot strength, in accordance
with previous findings [6,7,23,29]. Importantly, we found
that the variables independently associated with clot
strength changed with injury severity so that platelet
count only remained independently associated with clot
strength in the highest ISS group after adjusting for the
platelet activation level (sCD40L). Based on this finding it
could be speculated that trauma induced platelet activa-
tion (and ensuing release of sCD40L) may result in down-
stream platelet exhaustion or hypo responsiveness so the
platelets left could not adequately support clot formation.
Alternatively, the finding may simply reflect that ade-
quately activated platelets were consumed in vivo upon
clot formation leaving in the circulation (and collected
upon blood sampling) platelets with lower hemostatic
potential. The finding emphasizes that changes observed
in the blood may optimally be interpreted from a systems
biology perspective taking into account the condition of
the vascular endothelium (activated, damaged, leaky etc.)
surrounding the circulating blood and hence critically
influencing the composition of both the circulating and
sampled blood [20]. Whichever explanation, the notion
that severe trauma may result in platelet exhaustion is in
accordance with previous thoughts [30] and in accordance
with a recent study of platelet function in trauma patients
reporting on low platelet reactivity assessed by both Multi-
plate and by the platelet component of viscoelastic tests
(ROTEM) in patients with highest ISS and non-survivors
[31]. Finally, it should be noted that the fibrinogen values
included in the statistical model in the present study may
not adequately reflect fibrin polymerization (and hence
functional contribution to clot strength) since optical mea-
surements of circulating fibrinogen levels not always sim-
ply reflect fibrin polymerization.
Importantly, we also found that the adrenaline level was
negatively independently associated with clot strength only
in the highest ISS group indicating that excessive sym-
pathoadrenal activation may negatively influence hemosta-
sis. We recently proposed [20] and demonstrated [18] that
progressive increases in adrenaline levels in trauma
patients promote a switch from hypercoagulability towards
hypocoagulability and hyperfibrinolysis due to the influ-
ence of adrenaline on the vascular endothelium [19,20].
The finding here supports this notion and emphasizes that
the sympathoadrenal activation following trauma may
contribute directly to the early coagulopathy observed in
trauma patients.
Whether the different contribution of fibrinogen and
platelets to TEG clot strength in patients with high vs. low
injury severity reflects that these patients would benefit
from different resuscitation strategies with e.g., FFP/fibri-
nogen/cryoprecipitate pool vs. platelets cannot be
answered from the present explorative study but should
be investigated in a randomized clinical trial powered to
answer this question.
The results presented here are subject to the limita-
tions inherent to observational studies and, thereby, do
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relationship suggested. Furthermore, the low number of
subjects, and especially the low number of severely
injured patients and patients with hypocoagulable or
hyperfibrinolytic TEG profiles, included in the present
study increases the risk of introducing a type II error,
emphasizing that the reported findings should be con-
firmed in a larger cohort of patients. Finally, exclusion of
patients based on pre-hospital fluid administration (>
2,000 ml) could theoretically have introduced a bias by
excluding the most severely injured and bleeding
patients, which should be taken into account. However,
in 2004 our Trauma Centre introduced Hemostatic Con-
trol Resuscitation and abandoned colloids along with a
general consensus of restrictive pre-hospital crystalloid
fluid resuscitation so extremely few patients admitted to
o u rT r a u m aC e n t r ei nt h es t u d yp e r i o da n dt o d a yw e r e
resuscitated with > 2,000 ml fluids pre-hospital and no
patients received colloids.
Conclusions
This study demonstrates that trauma patients present with
a range of coagulopathies when evaluated by TEG and
that patients with hypercoagulable TEG are older and
have higher fibrinogen level and platelet count. Increasing
ISS was associated with more pronounced coagulopathy
and importantly, also with increased activated protein C
and reduced FXIII levels. The variables independently
associated with clot strength changed with injury severity
and in the most severely injured patients, adrenaline and
sCD40L were independently negatively associated with
maximum clot strength and platelet count was only asso-
ciated with clot strength after adjusting for platelet activa-
tion level. The latter finding indicates that excessive
sympathoadrenal activation and platelet activation in the
most severely injured patients may contribute to the acute
coagulopathy of trauma.
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